We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
+11.43%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$2.35B
AUM Growth
+$162M
Cap. Flow
+$9.89M
Cap. Flow %
0.42%
Top 10 Hldgs %
51.28%
Holding
86
New
9
Increased
45
Reduced
20
Closed
11

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$49.7M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$40.7M
3
INCY icon
Incyte
INCY
+$26.8M
4
PTCT icon
PTC Therapeutics
PTCT
+$26.4M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$21.2M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$96M
2
PFE icon
Pfizer
PFE
+$53.7M
3
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$46.4M
4
AGN
Allergan plc
AGN
+$36.3M
5
RLYP
RELYPSA INC COM
RLYP
+$15.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$167B
$180M 7.69%
1,782,298
-74,160
-4% -$7.72M
ALXN
2
DELISTED
Alexion Pharmaceuticals
ALXN
$145M 6.17%
758,180
+36,587
+5% +$6.39M
BMRN icon
3
BioMarin Pharmaceuticals
BMRN
$11.5B
$142M 6.07%
1,359,922
+390,099
+40% +$40.7M
CELG
4
DELISTED
Celgene Corp
CELG
$141M 6.01%
1,177,058
-90,100
-7% -$10.4M
REGN icon
5
Regeneron Pharmaceuticals
REGN
$70.9B
$128M 5.47%
236,300
-7,800
-3% -$4.23M
INCY icon
6
Incyte
INCY
$23.4B
$122M 5.21%
1,127,423
+240,372
+27% +$26.8M
BIIB icon
7
Biogen
BIIB
$30.4B
$89.1M 3.8%
290,889
-334,207
-53% -$96M
VRTX icon
8
Vertex Pharmaceuticals
VRTX
$123B
$86.6M 3.69%
688,200
-46,000
-6% -$5.55M
TMO icon
9
Thermo Fisher Scientific
TMO
$198B
$86.1M 3.67%
606,936
+1,300
+0.2% +$173K
AMGN icon
10
Amgen
AMGN
$198B
$81.9M 3.49%
504,597
-50,100
-9% -$7.88M
FOLD
11
DELISTED
Amicus Therapeutics
FOLD
$77.3M 3.3%
7,973,436
+1,862,209
+30% +$16.8M
MRK icon
12
Merck
MRK
$315B
$59.3M 2.53%
1,175,777
+25,727
+2% +$1.3M
SGEN
13
DELISTED
Seagen Inc. Common Stock
SGEN
$57.3M 2.44%
1,275,775
+6,700
+0.5% +$279K
XLRN
14
DELISTED
Acceleron Pharma
XLRN
$54.7M 2.33%
1,121,264
+509,080
+83% +$18.3M
PTCT icon
15
PTC Therapeutics
PTCT
$6.52B
$51.4M 2.19%
1,586,258
+895,894
+130% +$26.4M
LLY icon
16
Eli Lilly
LLY
$1.05T
$50.5M 2.15%
+599,245
New +$49.7M
MDT icon
17
Medtronic
MDT
$106B
$41.8M 1.78%
543,792
+17,840
+3% +$1.34M
TEVA icon
18
Teva Pharmaceuticals
TEVA
$37.3B
$39.8M 1.7%
605,922
+10,972
+2% +$678K
HALO icon
19
Halozyme
HALO
$9.23B
$36M 1.53%
2,075,796
-595,255
-22% -$9.49M
SHPG
20
DELISTED
Shire pic
SHPG
$33.8M 1.44%
164,674
+42,618
+35% +$8.86M
ICPT
21
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$32.9M 1.4%
220,047
+400
+0.2% +$67.7K
VTRS icon
22
Viatris
VTRS
$20.1B
$32.5M 1.39%
601,910
+184,828
+44% +$8.89M
ALDR
23
DELISTED
Alder Biopharmaceuticals
ALDR
$30.9M 1.32%
934,951
+172,269
+23% +$5.83M
UTHR icon
24
United Therapeutics
UTHR
$22.7B
$30.6M 1.3%
195,280
+19,500
+11% +$2.84M
DXCM icon
25
DexCom
DXCM
$29.6B
$29.7M 1.27%
1,450,932
+158,000
+12% +$3.29M
1
2 3 4

Similar funds

RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $121M AUM 74.36% 1-Year Est. Return
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
FWA
Fulcrum Wealth Advisors Bellevue, Washington $121M AUM
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
WIM
Wiregrass Investment Management Thomasville, Georgia $121M AUM
MW
Merited Wealth North Bay Village, Florida $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM

Sectoral Asset Management's Q4 2015 Portfolio in Review

As of Q4 2015, Sectoral Asset Management held 86 positions worth $2.35B, up 7.4% from $2.18B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Sectoral Asset Management's Q4 2015 filing shows 9 new, 45 increased, 20 reduced and 11 closed positions. Its largest new stake was Eli Lilly: 599,245 shares worth $50.5M. The largest sale was Biogen, an estimated $96M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 94% a quarter earlier.

  • Sectoral Asset Management's largest Q4 2015 buy was Eli Lilly: 599,245 shares worth $50.5M.
  • Sectoral Asset Management added most to BioMarin Pharmaceuticals in Q4 2015, an estimated $40.7M increase.
  • Sectoral Asset Management's biggest Q4 2015 reduction was Biogen, cutting an estimated $96M.
  • Sectoral Asset Management fully exited Pfizer in Q4 2015, selling an estimated $53.7M.
  • Sectoral Asset Management's ten largest holdings make up 51% of its $2.35B portfolio in Q4 2015.
  • Sectoral Asset Management opened 9 new positions and closed 11 in Q4 2015.
  • Sectoral Asset Management's portfolio value rose 7.4% quarter-over-quarter to $2.35B.

Based on Sectoral Asset Management's 13F filing for Q4 2015, filed 12 Feb 2016.